Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | EPOR | P19235 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516143 | 1.00 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL29557381 | 1.00 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL22804087 | 0.96 | KMT2A (0.45) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL28836337 | 0.94 | KMT2A (0.42) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL5692815 | 0.94 | KMT2A (0.42) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL29908075 | 0.94 | KMT2A (0.42) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL5692740 | 0.94 | KMT2A (0.42) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL31729494 | 0.94 | KMT2A (0.42) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL20357217 | 0.93 | KMT2A (0.41) | KMT2ATLR2FABP5FABP7EPHX2 | |
| SCHEMBL20357215 | 0.93 | KMT2A (0.41) | KMT2ATLR2FABP5FABP7EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-4412662-A1 | PEPTIDE DENDRONS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | PEPTIAID INC (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240148664-A1 | LIPID AND COMPOSITION | SOGO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4340890-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | Purdue Research Foundation (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4326320-A1 | ADJUVANTED VACCINE COMPOSITION AND METHODS | D4 LABS, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024038152-A1 | COMPOSITIONS FOR FIBREBOARDS WITH ENHANCED PROPERTIES UPON FAST-CURING AT LOW TEMPERATURE | COVESTRO (NETHERLANDS) B.V. (NL) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024038153-A1 | COMPOSITIONS FOR FIBREBOARDS WITH ENHANCED PROPERTIES UPON FAST-CURING AT LOW TEMPERATURE | COVESTRO (NETHERLANDS) B.V. (NL) | 2024-02-22 | — | — | WO | disclosed |
| EP-4321524-A1 | LIPID AND COMPOSITION | Sogo Pharmaceutical Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| EP-4317174-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | Peptiaid Inc (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20100222539-A1 | Production and use of highly functional, highly branched or hyperbranched polylysines | BASF SE (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7786240-B2 | Reacting a salt of lysine with at least one acid in the presence of a tertiary amine or amidine, or an organometallic compound; additional reactants may include another amino acid, a di- or polycarboxylic acid, a di- or polyamine or derivative | BASF AKTIENGESELLSCHAFT (DE) | 2010-08-31 | — | — | US | disclosed |
| EP-2194063-A2 | Production and use of modified polylysines | BASF SE (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1957519-B1 | PRODUCTION OF HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYLYSINES | BASF SE (DE) | 2010-05-19 | — | — | EP | disclosed |
| EP-2176276-A2 | DERIVATIVES OF NYSTATIN AND THEIR USE AS ANTIFUNGAL AGENTS | Biosergen As (NO) | 2010-04-21 | — | — | EP | disclosed |
| US-20090048416-A1 | Reacting a salt of lysine with at least one acid in the presence of a tertiary amine or amidine, or an organometallic compound; additional reactants may include another amino acid, a di- or polycarboxylic acid, a di- or polyamine or derivative | BASF SE (DE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009004322-A2 | DERIVATIVES OF NYSTATIN AND THEIR USE AS ANTIFUNGAL AGENTS | BIOSERGEN AS (NO) | 2009-01-08 | — | — | WO | disclosed |
| EP-1957519-A1 | PRODUCTION AND USE OF HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYLYSINES | BASF SE (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007060119-A1 | PRODUCTION AND USE OF HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYLYSINES | BASF SE (DE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1458378-B1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148664-A1 | LIPID AND COMPOSITION | PLIN3, PLIN1, FABP1 | KMT2A 893/4885TLR2 790/4885FABP5 72/4885 |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | NGLY1, VIP, HM13 | KMT2A 2534/4885TLR2 4628/4885FABP5 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.